Navigation Links
Cardium Presents First Quarter 2012 Financial Results and Recent Developments
Date:5/15/2012

eter, combined with the intracoronary co-infusion of nitroglycerin, substantially enhanced adenovector-mediated gene expression in the heart. Use of these newly applied gene transfer techniques increased the efficiency of gene transfer in preclinical studies by more than two orders of magnitude (p<0.001). These findings have been incorporated into the protocol for the ASPIRE study and the new data underscore the expected benefit of Cardium's improved adenovector administration methods.  Use of combined non-surgical, percutaneous balloon catheter-based delivery with transiently-induced ischemia and nitroglycerin to enhance uptake is expected to lead to improved microvascular circulation in the heart. By increasing gene transfer efficiency, this modified delivery approach allows maximizing targeted expression of FGF-4 protein within the ischemic heart of all treated patients, where the resulting angiogenesis or blood vessel growth can bring about improved blood flow.  Traditional interventional approaches such as coronary artery bypass surgery (CABG) or angioplasty and stenting (PCI), not only require invasive and costly surgical procedures but they can only directly target selected vulnerable spots in larger vessels that are susceptible to treatment and reachable through mechanical intervention. 

Additional information about Generx and the ASPIRE study is available in a Company presentation titled, Generx Angiogenic Therapy: Regenerative Medicine for Interventional Cardiology, at http://phx.corporate-ir.net/phoenix.zhtml?c=77949&p=irol-presentations and by viewing, "Cardium Generx Cardio-Chant" at http://www.youtube.com/watch?v=pjUndFhJkjM.

MedPodium's Healthy Lifestyle BrandDuring first quarter 2012, Cardium partnered with Nutritional Productions International (NPI) and InHealth Med
'/>"/>

SOURCE Cardium Therapeutics
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10 11

Related biology technology :

1. Cardium to Present at Upcoming Investor Conferences
2. Cardiums Exchange Listing Compliance Plan Accepted by NYSE Amex
3. Cardium Reports Excellagen Matrix Clinical Study Results Accepted for Publication by Peer-Reviewed Journal, and Updates Product Plans
4. Cardium Reports on Third Quarter 2010 Financial Results and Recent Developments
5. Cardium to Present at the LifeTech Capital Miami Medical Investors Conference
6. Cardium Gains Exclusive Access to Novel Polymer-Based Nitric Oxide Technology for Expansion of Wound Healing Product Portfolio
7. Cardium to Present at 10th Annual Biotech in Europe Investor Forum
8. Cardium Regains Listing Compliance With NYSE Amex
9. Cardium to Present at MDB Capital Groups 2010 Bright Lights Conference
10. Cardiums Exchange Listing Compliance Plan Accepted by NYSE AMEX
11. Cardium Reports on Third Quarter 2009 Financial Results and Recent Developments
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/2/2015)... PARK, Calif. , March 2, 2015  Asterias ... in the emerging field of regenerative medicine, today announced ... 2014 financial and operating results on Tuesday, March 10, ... The Company will host a conference call and webcast ... / 1:30 p.m. Pacific to discuss the results and ...
(Date:3/2/2015)... Boston, Massachusetts (PRWEB) March 02, 2015 ... legal services, today announced the addition of Debbie Casey ... group’s capabilities in the healthcare space. , ... industry, most of which with Fresenius Medical Care North ... will leverage her extensive experience to work with Outside ...
(Date:2/27/2015)... SUMMERLAND, British Columbia , Feb. 27, ... XON ), a leader in synthetic biology, today announced ... Specialty Fruits (OSF), the pioneering agricultural company behind ... first non-browning apple. Through the acquisition, Intrexon expands its ... more appetizing and convenient for consumers while providing economic ...
(Date:2/27/2015)... (PRWEB) February 27, 2015 Immunovaccine ... and immunotherapy company, today announced that the U.S. ... for Fast Track designation and Phase I clinical ... conjunction with the mutual co-development agreement signed with ... Fast Track designation for the DPX-Survivac. , “We ...
Breaking Biology Technology:Asterias Biotherapeutics to Report Fourth Quarter and Full Year 2014 Results on March 10, 2015 2Outside GC Expands Healthcare Team 2Intrexon to Acquire Okanagan Specialty Fruits 2Intrexon to Acquire Okanagan Specialty Fruits 3Intrexon to Acquire Okanagan Specialty Fruits 4Immunovaccine Inc. (TSX: IMV) receives Fast Track and Phase I trial approval for Ebola and Anthrax vaccine programs, signs co-development agreement with Gilead Sciences 2Immunovaccine Inc. (TSX: IMV) receives Fast Track and Phase I trial approval for Ebola and Anthrax vaccine programs, signs co-development agreement with Gilead Sciences 3
... This release is available in Spanish . ... leading in Spain the European project within the VII Framework ... buildings which host large numbers of people, such as sports ... by the management and optimisation of energy in its three ...
... 5, 2011 Sangamo BioSciences, Inc. (Nasdaq: SGMO ... will provide an update on the progress of Sangamo,s ZFP ... strategy at 12:30 pm PT (3:30 pm ET) on Thursday, ... Conference which will be held in San Francisco. ...
... HOUSTON, Jan. 5, 2011 International energy pricing agency ... expansion into US and Canadian wood chip pricing complements ... broader European biomass indexation. " Argus understands ... to be at the forefront, providing transparency to emerging biomass ...
Cached Biology Technology:Tecnalia leads the integration of energy efficiency in sports facilities 2Sangamo BioSciences Announces Presentation at J.P. Morgan Healthcare Conference 2Argus Launches North American Wood Chip Price Assessments 2
(Date:2/23/2015)... 23, 2015 NXT-ID, Inc. (NASDAQ: ... biometric authentication company focused on the growing mobile commerce ... 62114357 for DISTRIBUTED VOICE DIRECTED PAYMENT METHOD ... a new groundbreaking payment method. Payment accounts may be ... only be accessed if both the speech (the word ...
(Date:2/18/2015)... 2015  Cepheid (NASDAQ: CPHD ) today announced ... and invited investors to participate via webcast. , Cowen ... Tuesday, March 3, 2015 at 11.20 a.m. Eastern Time ... FL Wednesday, March 4, 2015 at 10.25 a.m. ... live webcasts for these events, please visit Cepheid,s website at ...
(Date:2/12/2015)...   MedNet Solutions , a global life ... systems, has recently bolstered its iMedNet™ ... iMedNet as the eClinical solution of ... consultants.  Building on the Program,s existing benefits (including ... co-marketing opportunities), MedNet,s new and improved program provides ...
Breaking Biology News(10 mins):NXT-ID Patents Voice Directed Payments 2NXT-ID Patents Voice Directed Payments 3Cepheid to Webcast Upcoming Financial Presentations 2MedNet Solutions Announces Key Enhancements To Its iMedNet Partner Program 2
... intimately familiar with the awe-inspiring photos of space shuttle launches ... But how many people have paused for even a second ... a two-week space shuttle mission or are living for months ... book The Astronaut,s Cookbook Tales, Recipes, and More ...
... 13 BIO-key International, Inc. (OTC Bulletin Board: BKYI), ... identification solutions, today reported results for the third quarter ... The Company,s results reflected operating profitability for each quarter ... (Logo: http://www.newscom.com/cgi-bin/prnh/20050509/BIOKEYLOGO ) , As a result of ...
... DALLAS Nov. 12, 2009 UT Southwestern ... to date for basic and patient-oriented research from the ... billion stimulus package President Barack Obama signed into law ... the National Science Foundation (NSF) and the National Institutes ...
Cached Biology News:The astronaut's cookbook 2BIO-key(R) Reports Fourth Consecutive Quarter of Operating Profitability 2BIO-key(R) Reports Fourth Consecutive Quarter of Operating Profitability 3BIO-key(R) Reports Fourth Consecutive Quarter of Operating Profitability 4BIO-key(R) Reports Fourth Consecutive Quarter of Operating Profitability 5BIO-key(R) Reports Fourth Consecutive Quarter of Operating Profitability 6UT Southwestern receives $42 million in Recovery Act stimulus funding 2UT Southwestern receives $42 million in Recovery Act stimulus funding 3
MAb to HSV-2, gG-2 HSV-2 Glycoprotein G-2...
Immunogen for A300-655A was a phosphorylated synthetic peptide, which represented a portion of human RNA Polymerase II (GeneID 5430) around serine 5 of the C-terminal repeat YSPTSPS....
human Exodus-2 Research Focus: cytokine/growth factor Storage Temperature: -20C Shipping Temperature: 4C...
MAb to IgG2 (Fc gamma-2) IgG2 (Fc, gamma-2 epitope)...
Biology Products: